Ask AI

Identify and Inform: Best Practices to Optimize Proficiency in the Assessment of HER2-Altered Solid Tumors

Improve your ability to accurately evaluate HER2 in patients with HER2-altered solid tumors and personalize treatment based on the latest clinical trial evidence and FDA approvals through an expert-authored ClinicalThought commentary and certified on-demand webcast with accompanying downloadable slides.

Share

Program Content

Events

Activities

HER2 Testing in GI Cancers
HER2 Testing in GI Cancers
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 24, 2026

HER2 Testing in NSCLC
HER2 Testing in NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 24, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.